Scotiabank Maintains Sector Perform on Janux Therapeutics, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Perform rating on Janux Therapeutics (NASDAQ:JANX) but lowers the price target from $47 to $42.
August 09, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Scotiabank analyst George Farmer maintains a Sector Perform rating on Janux Therapeutics but lowers the price target from $47 to $42.
The lowered price target from $47 to $42 suggests a less optimistic outlook for Janux Therapeutics, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100